STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

SCIENTURE HOLDINGS (NASDAQ: SCNX) announced management will participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference on December 9–10, 2025. Narasimhan Mani, President and co-CEO, will present at 2:00 PM ET on December 9. Shankar Hariharan, Executive Chairman and co-CEO, will join one-on-one investor meetings on December 10. A live webcast of the presentation is available at the conference link and a replay will be posted on the company’s investor site under Events and Presentations. The two-day event features Day 1 webcasts and Day 2 one-on-one investor meetings for pre-qualified investors.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

COMMACK, NY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that management will be participating in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th - 10th, 2025.

Narasimhan Mani, President and co-CEO of Scienture is scheduled to present at 2:00 PM EST on December 9th. Shankar Hariharan, Executive Chairman and co-CEO of Scienture, will join him for one-on-one meetings with investors on December 10th.

The live webcast of Scienture’s presentation will be available at https://www.webcaster5.com/Webcast/Page/3148/53307, and a replay will be accessible afterward. The presentation will also be available on the Company’s website at https://scientureholdings.com/investors/ under the "Events and Presentations" tab.

iAccess Alpha hosts virtual investor conferences featuring high-potential small and micro-cap companies as investment opportunities. These two-day events include webcast presentations on Day 1, followed by one-on-one meetings between company management teams and pre-qualified investors on Day 2.

For more information about the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025, or to register and schedule a one-on-one meeting with Scienture, please visit the conference website at: https://www.iaccessalpha.com.

About Scienture Holdings, Inc.

SCIENTURE HOLDINGS, INC. (NASDAQ: “SCNX”), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: www.scientureholdings.com and www.scienture.com.

Cautionary Statements Regarding Forward-Looking Statements

This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, the success those products may have in the marketplace, and our strategies related to those products. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.

Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.

Contact:

SCIENTURE HOLDINGS, INC.
20 Austin Blvd
Commack, NY 11725
Phone: (866) 468-6535
Email: IR@Scienture.com


FAQ

When will SCIENTURE (SCNX) present at the iAccess Alpha Winter Investment Conference 2025?

SCIENTURE will present on December 9, 2025 at 2:00 PM ET.

How can investors watch the SCIENTURE (SCNX) live presentation on December 9, 2025?

The live webcast is available at the conference webcast link and a replay will be posted on SCIENTURE’s investor site under Events and Presentations.

Who from SCIENTURE (SCNX) will be available for investor meetings on December 10, 2025?

Shankar Hariharan, Executive Chairman and co-CEO, will join one-on-one investor meetings on December 10, 2025.

Where is the SCIENTURE (SCNX) presentation replay posted after the conference?

The replay will be accessible on SCIENTURE’s investor website at https://scientureholdings.com/investors/ under Events and Presentations.

What is the format of the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025?

The conference includes Day 1 webcast presentations and Day 2 one-on-one meetings between management teams and pre-qualified investors.

How can investors register or schedule a one-on-one meeting with SCIENTURE (SCNX) at the conference?

Investors can register and request one-on-one meetings via the conference website at https://www.iaccessalpha.com.
Scienture Holdings, Inc

NASDAQ:SCNX

SCNX Rankings

SCNX Latest News

SCNX Latest SEC Filings

SCNX Stock Data

24.34M
33.79M
25.78%
1.56%
0.67%
Pharmaceutical Retailers
Pharmaceutical Preparations
Link
United States
COMMACK